To confirm the therapeutic effect of BCL‐2 inhibitor combined with Apatinib on DLBCL in vivo, we tested the efficacy of ABT‐199 plus Apatinib in the BALB/C nude mice (Fig. 3A). Here, BCL2 is linked to diffuse large B-cell lymphoma.